HIV pre-exposure prophylaxis (PrEP) is highly effective at preventing HIV; however, PrEP
use among transgender individuals remains low. We conducted a systematic review to …

Background: Delivery and use of HIV pre-exposure prophylaxis (PrEP) are suboptimal in the
United States. Previous reviews of barriers and facilitators have not used an implementation …

Despite the high efficacy of pre-exposure prophylaxis (PrEP) in preventing HIV acquisition,
PrEP uptake among Black cisgender women remains low. Our qualitative study assessed …

Background Strengthening HIV prevention is imperative given the continued high HIV
incidence worldwide. The introduction of oral PrEP as a new biomedical HIV prevention tool …

Objective: Pre-exposure prophylaxis (PrEP) is a recommended strategy for HIV prevention,
yet PrEP prescribing rates in primary care remain low. The aim of this study was to further …

Intramuscular cabotegravir for long-acting injectable HIV pre-exposure prophylaxis (ie, LAI-
PrEP) was approved by the US FDA in 2021. We sought to explore LAI-PrEP decision …

Alternatives to daily dosing of HIV pre-exposure prophylaxis (PrEP) are continuing to
emerge. From October 2019 to March 2020, we conducted an online survey of PrEP …

Differentiated service delivery and new products, such as long-acting injectable cabotegravir
(CAB-LA) and the dapivirine vaginal ring (DVR), could increase uptake and use of pre …

Pre-exposure prophylaxis (PrEP) is an effective biomedical strategy for HIV prevention. This
umbrella review is aimed at providing a comprehensive summary of the current status of …

Importance HIV preexposure prophylaxis (PrEP) is a key component of the Ending the HIV
Epidemic (EHE) Initiative to curb new HIV diagnoses. In October 2019 …